Phase I/ II study of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.

Phase I/ II study of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. - S-1 and cisplatin with concurrent radiotherapy for NSCLC.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005389

Enrollment

Registered

2011-04-06

Start date

2005-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Level 1

CDDP 60 mg/m2, day 8 S-1 80 mg/m2 days 1-14 every 3weeks Level 2

CDDP 60 mg/m2, day 8 S-1 80 mg/m2 days 1-21 every 4weeks Thoracic radiation 60Gy/30fr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligibility criteria were: histological or cytological diagnosis of unresectable stage III NSCLC; no prior chemotherapy; measurable lesions; PS (ECOG) 0-1; adequate hematology and biochemistry parameters; and informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria were:active concomitant malignancy; active pulmonary fibrosis or interstitial pneumonia ; watery diarrhea; serious complications; pregnancy; psychotic disorder; and drug allergy.

Design outcomes

Primary

Measure	Time frame
2-year survival rate	—

Secondary

Measure	Time frame
objective response rate,overall survival,progression-free survival,toxicity	—

Countries

Japan

Contacts

Public ContactTetsuhiko Taira

National Cancer Center Hospital East Division of Thoracic Oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026